The Zhitong Finance App learned that AstraZeneca (AZN.US) today announced the positive results of the Capitello-281 phase 3 clinical trial. The analysis showed that for patients with PTEN-deficient metastatic hormone-sensitive prostate cancer (MHSPC), AstraZeneca's Truqap (capivasertib) combined with abiraterone (abiraterone) and androgen deprivation therapy (ADT) showed statistically significant and clinically significant improvements in the main endpoints of radiologically-progressive survival (RPFs) compared with abiraterone and ADT combined placebo. According to reports, the TruQap combination is the first AKT inhibitor combination proven to be beneficial for this specific subtype of prostate cancer.

Zhitongcaijing · 6d ago
The Zhitong Finance App learned that AstraZeneca (AZN.US) today announced the positive results of the Capitello-281 phase 3 clinical trial. The analysis showed that for patients with PTEN-deficient metastatic hormone-sensitive prostate cancer (MHSPC), AstraZeneca's Truqap (capivasertib) combined with abiraterone (abiraterone) and androgen deprivation therapy (ADT) showed statistically significant and clinically significant improvements in the main endpoints of radiologically-progressive survival (RPFs) compared with abiraterone and ADT combined placebo. According to reports, the TruQap combination is the first AKT inhibitor combination proven to be beneficial for this specific subtype of prostate cancer.